Michael Julius

Dr. Michael Julius is past Vice President, Research at Sunnybrook Health Sciences Centre (2000-2020). He created an international hub for life sciences dedicated to both discovery and commercialization. This initiative achieved a functional integration of researchers, clinicians, business and patients towards moving discoveries into the clinic. He shepherded growth to a $125M annual research enterprise which spun off 15 companies over his tenure. Michael is currently partnering in the launch of a life sciences capital management fund.

Ahead of taking on his leadership position at Sunnybrook, Michael Chaired the Department of Immunology at the University of Toronto (1994-2000). He has Chaired both the Canadian Institutes for Health Research review panel for Immunology and Transplantation and Research Canada, an advocacy corporation dedicated to ensuring that the federal government supports and funds the priority of health research in Canada. He serves as a member of Scientific Advisory Boards for a number of companies and has Chaired two of Sunnybrook’s spin-off companies.

Michael completed his undergraduate degree in genetics at McGill University and his doctoral work in genetics and immunology at Stanford University. Michael was recruited to the Basel Institute for Immunology supported by Hoffman La Roche, where he remained for the 13 years. Having published over 200 research papers and reviews in his area of expertise, many of which have achieved citation records, Michael has in-depth knowledge of multiple therapeutic areas, including neuroscience, cancer, cardiovascular and immune system; and expertise across multiple platforms, including high content cellular analyses, AI, health informatics, and imaging-guided interventions and therapeutics.